Salvage Surgery for Patients With Local Recurrence or Persistent Disease After Treatment With Chemoradiotherapy for SCLC

Pieter J. M. Joosten, Toon A. Winkelman, David J. Heineman, Sayed M. S. Hashemi, Idris Bahce, Suresh Senan, Marinus A. Paul, Koen J. Hartemink, Max Dahele, Chris Dickhoff*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Introduction: The role of salvage surgery for patients with locoregional (LR) recurrence or persistent SCLC after radical chemoradiotherapy (CRT) for limited-stage disease is not well established. We evaluated our experience. Methods: We conducted a retrospective study of consecutive patients who underwent salvage pulmonary resection for LR-recurrent or persistent SCLC between 2008 and 2020 at the Amsterdam University Medical Center. Results: A total of 10 patients were identified. Median age at initial diagnosis of limited-stage SCLC was 58.5 years (48–71 y). All patients had radical-intent concurrent CRT. Of the 10 patients, 9 were diagnosed with LR-recurrent or persistent disease with a median of 18 months (3–78 y) after CRT. All patients underwent an anatomical radical resection and mediastinal lymph node dissection. No 90-day mortality was recorded. In addition, one patient developed a LR recurrence 7 months after resection. Distant progression was found in three patients at 6, 32, and 61 months after surgery, all of whom subsequently died of progressive SCLC. Median follow-up was 22.5 months (2–86 mos). Disease-free survival was 34 months; overall survival was not reached. Conclusions: For highly selected patients with LR-recurrent or persistent SCLC after CRT, salvage surgery is feasible and can result in clinically meaningful survival. Such patients should be presented to the multidisciplinary tumor board.
Original languageEnglish
Article number100172
JournalJTO Clinical and Research Reports
Issue number5
Publication statusPublished - 1 May 2021

Cite this